NCT00760396

Multiple-Dose Study of VGX-1027 in Healthy Subjects

A Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety and Pharmacokinetics of VGX-1027 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: VGX Pharmaceuticals, LLC · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety profile, tolerability and pharmacokinetics following multiple oral doses of 40mg to 200mg VGX 1027 in healthy subjects administered for 5 days.

Detailed description

This study will evaluate: * The safety and tolerability of multiple oral doses of VGX 1027 in the range of 40 to 400mg. * The pharmacokinetics of VGX 1027 in healthy subjects following the first oral dose (Day 1) and at steady state (Day 5).

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	VGX-1027	Subjects will

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-11-01
• Completion: 2009-04-01
• First posted: 2008-09-26
• Last updated: 2009-04-07

Locations

1 site across 1 country: United States